The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue

Patrizia Chiusolo; Sabrina Giammarco; Silvia Bellesi; Elisabetta Metafuni; Nicola Piccirillo; Daniela Giovanna De Ritis; Sara Marietti; Sorà Federica; Luca Laurenti; Luana Fianchi; Stefan Hohaus; Giuseppe Leone; Simona Sica

doi:10.1007/s00280-011-1751-4

The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue

Patrizia Chiusolo
, Sabrina Giammarco
, Silvia Bellesi
, Elisabetta Metafuni
, Nicola Piccirillo
, Daniela Giovanna De Ritis
, Sara Marietti
, Sorà Federica
, Luca Laurenti
, Luana Fianchi
, Stefan Hohaus
, Giuseppe Leone
, Simona Sica

Research output: Contribution to journal › Article

31 Citations (Scopus)

Abstract

In the last years, the influence of different genes involved in metabolism of chemotherapeutic agents has been studied. Methotrexate (MTX) is a key compound of chemotherapeutic regimens used in the treatment of acute lymphoblastic leukemia (ALL), primary central nervous system lymphoma (PCNSL) and Burkitt's lymphomas (BL). This study aims to evaluate the role of MTHFR C677T and A1298C polymorphisms and G80A reduced folate carrier gene (RFC1) in a cohort of adult patients with lymphoproliferative malignancies submitted to high-dose MTX followed by leucovorin rescue.

Original language	English
Pages (from-to)	691-696
Number of pages	6
Journal	Cancer Chemotherapy and Pharmacology
Volume	69
DOIs	https://doi.org/10.1007/s00280-011-1751-4
Publication status	Published - 2012

Keywords

Adolescent
Adult
Aged
Animals
Antineoplastic Combined Chemotherapy Protocols
Cohort Studies
Disease-Free Survival
Hematologic Neoplasms
Humans
Kaplan-Meier Estimate
Leucovorin
Male
Methotrexate
Methylenetetrahydrofolate Reductase (NADPH2)
Middle Aged
Polymorphism, Genetic
Reduced Folate Carrier Protein
Young Adult

Access to Document

10.1007/s00280-011-1751-4

Cite this

Chiusolo, P., Giammarco, S., Bellesi, S., Metafuni, E., Piccirillo, N., De Ritis, D. G., Marietti, S., Federica, S., Laurenti, L., Fianchi, L., Hohaus, S., Leone, G., & Sica, S. (2012). The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue. Cancer Chemotherapy and Pharmacology, 69, 691-696. https://doi.org/10.1007/s00280-011-1751-4

@article{b738c822501d418bbfcfaf6efc5c2b14,

title = "The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue",

abstract = "In the last years, the influence of different genes involved in metabolism of chemotherapeutic agents has been studied. Methotrexate (MTX) is a key compound of chemotherapeutic regimens used in the treatment of acute lymphoblastic leukemia (ALL), primary central nervous system lymphoma (PCNSL) and Burkitt's lymphomas (BL). This study aims to evaluate the role of MTHFR C677T and A1298C polymorphisms and G80A reduced folate carrier gene (RFC1) in a cohort of adult patients with lymphoproliferative malignancies submitted to high-dose MTX followed by leucovorin rescue.",

keywords = "Adolescent, Adult, Aged, Animals, Antineoplastic Combined Chemotherapy Protocols, Cohort Studies, Disease-Free Survival, Hematologic Neoplasms, Humans, Kaplan-Meier Estimate, Leucovorin, Male, Methotrexate, Methylenetetrahydrofolate Reductase (NADPH2), Middle Aged, Polymorphism, Genetic, Reduced Folate Carrier Protein, Young Adult, Adolescent, Adult, Aged, Animals, Antineoplastic Combined Chemotherapy Protocols, Cohort Studies, Disease-Free Survival, Hematologic Neoplasms, Humans, Kaplan-Meier Estimate, Leucovorin, Male, Methotrexate, Methylenetetrahydrofolate Reductase (NADPH2), Middle Aged, Polymorphism, Genetic, Reduced Folate Carrier Protein, Young Adult",

author = "Patrizia Chiusolo and Sabrina Giammarco and Silvia Bellesi and Elisabetta Metafuni and Nicola Piccirillo and \{De Ritis\}, \{Daniela Giovanna\} and Sara Marietti and Sor{\`a} Federica and Luca Laurenti and Luana Fianchi and Stefan Hohaus and Giuseppe Leone and Simona Sica",

year = "2012",

doi = "10.1007/s00280-011-1751-4",

language = "English",

volume = "69",

pages = "691--696",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Science and Business Media Deutschland GmbH",

}

Chiusolo, P, Giammarco, S, Bellesi, S, Metafuni, E, Piccirillo, N, De Ritis, DG, Marietti, S, Federica, S, Laurenti, L , Fianchi, L , Hohaus, S, Leone, G & Sica, S 2012, 'The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue', Cancer Chemotherapy and Pharmacology, vol. 69, pp. 691-696. https://doi.org/10.1007/s00280-011-1751-4

TY - JOUR

T1 - The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue

AU - Chiusolo, Patrizia

AU - Giammarco, Sabrina

AU - Bellesi, Silvia

AU - Metafuni, Elisabetta

AU - Piccirillo, Nicola

AU - De Ritis, Daniela Giovanna

AU - Marietti, Sara

AU - Federica, Sorà

AU - Laurenti, Luca

AU - Fianchi, Luana

AU - Hohaus, Stefan

AU - Leone, Giuseppe

AU - Sica, Simona

PY - 2012

Y1 - 2012

N2 - In the last years, the influence of different genes involved in metabolism of chemotherapeutic agents has been studied. Methotrexate (MTX) is a key compound of chemotherapeutic regimens used in the treatment of acute lymphoblastic leukemia (ALL), primary central nervous system lymphoma (PCNSL) and Burkitt's lymphomas (BL). This study aims to evaluate the role of MTHFR C677T and A1298C polymorphisms and G80A reduced folate carrier gene (RFC1) in a cohort of adult patients with lymphoproliferative malignancies submitted to high-dose MTX followed by leucovorin rescue.

AB - In the last years, the influence of different genes involved in metabolism of chemotherapeutic agents has been studied. Methotrexate (MTX) is a key compound of chemotherapeutic regimens used in the treatment of acute lymphoblastic leukemia (ALL), primary central nervous system lymphoma (PCNSL) and Burkitt's lymphomas (BL). This study aims to evaluate the role of MTHFR C677T and A1298C polymorphisms and G80A reduced folate carrier gene (RFC1) in a cohort of adult patients with lymphoproliferative malignancies submitted to high-dose MTX followed by leucovorin rescue.

KW - Adolescent

KW - Adult

KW - Aged

KW - Animals

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Cohort Studies

KW - Disease-Free Survival

KW - Hematologic Neoplasms

KW - Humans

KW - Kaplan-Meier Estimate

KW - Leucovorin

KW - Male

KW - Methotrexate

KW - Methylenetetrahydrofolate Reductase (NADPH2)

KW - Middle Aged

KW - Polymorphism, Genetic

KW - Reduced Folate Carrier Protein

KW - Young Adult

KW - Adolescent

KW - Adult

KW - Aged

KW - Animals

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Cohort Studies

KW - Disease-Free Survival

KW - Hematologic Neoplasms

KW - Humans

KW - Kaplan-Meier Estimate

KW - Leucovorin

KW - Male

KW - Methotrexate

KW - Methylenetetrahydrofolate Reductase (NADPH2)

KW - Middle Aged

KW - Polymorphism, Genetic

KW - Reduced Folate Carrier Protein

KW - Young Adult

UR - http://hdl.handle.net/10807/6033

U2 - 10.1007/s00280-011-1751-4

DO - 10.1007/s00280-011-1751-4

M3 - Article

SN - 0344-5704

VL - 69

SP - 691

EP - 696

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

ER -

The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this